The company's validation studies demonstrate that the assay has a 99 percent negative predictive value, which it believes will persuade physicians of its value.
The investment bank gave Exact Sciences' shares a price target of $30, and said it expects higher uptake of the Cologuard test and an increase in payor contracts.
The computational method, called DeepCpG, is designed to tease out missing epigenetic marks and related DNA motifs in single-cell DNA methylation data.
MethylCap-seq data for dozens of primary endometrioid endometrial cancers led to a 13-region methylation signature linked to broader tumor genome features.
Yale Environment 360 writes that synthetic and conservation biologists aren't always on the same wavelength, but they are trying to reach an understanding.
